So-mi Kang

Dr. So-mi Kang

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2020 in Cells
Verified
Journal Article
Open access
PDF file
JAJinsook Ahn
Jinsook Ahn
SJSoyeon Jeong
Soyeon Jeong
SKSo-mi Kang
So-mi Kang
IJInseong Jo
Inseong Jo
BPBum-Joon Park
Bum-Joon Park
NHNam-Chul Ha
Nam-Chul Ha
Intermediate filaments (IFs) commonly have structural elements of a central α-helical coiled-coil domain consisting of coil 1a, coil 1b, coil 2, and their flanking linkers. Recently, the crystal structure of a long lamin A/C fragment was determined and showed detailed features of a tetrameric unit. The structure further suggested a new binding mode between tetramers, designated eA22, where a parallel overlap of coil 1a and coil 2 is the critical interaction. This study investigated the biochemical effects of genetic mutations causing human diseases, focusing on the eA22 interaction. The mutant proteins exhibited either weakened or augmented interactions between coil 1a and coil 2. The ensuing biochemical results indicated that the interaction requires the separation of the coiled-coils in the N-terminal of coil 1a and the C-terminal of coil 2, coupled with the structural transition in the central α-helical rod domain. This study provides insight into the role of coil 1a as a molecular regulator in the elongation of IF proteins.

1 April 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JAJinsook Ahn
Jinsook Ahn
JLJinwook Lee
Jinwook Lee
SJSoyeon Jeong
Soyeon Jeong
SKSo-mi Kang
So-mi Kang
BPBum-Joon Park
Bum-Joon Park
NHNam-Chul Ha
Nam-Chul Ha

Verified
Journal Article
Open access
PDF file
BKBae-Hoon Kim
Bae-Hoon Kim
YCYeon-Ho Chung
Yeon-Ho Chung
TWTae-Gyun Woo
Tae-Gyun Woo
SKSo-mi Kang
So-mi Kang
SPSoyoung Park
Soyoung Park
BPBum-Joon Park
Bum-Joon Park
NF2-related schwannomatosis (NF2) is a genetic syndrome characterized by the growth of benign tumors in the nervous system, particularly bilateral vestibular schwannomas, meningiomas, and ependymomas. This review consolidates the current knowledge on NF2 syndrome, emphasizing the molecular pathology associated with the mutations in the gene of the same name, the NF2 gene, and the subsequent dysfunction of its product, the Merlin protein. Merlin, a tumor suppressor, integrates multiple signaling pathways that regulate cell contact, proliferation, and motility, thereby influencing tumor growth. The loss of Merlin disrupts these pathways, leading to tumorigenesis. We discuss the roles of another two proteins potentially associated with NF2 deficiency as well as Merlin: Yes-associated protein 1 (YAP), which may promote tumor growth, and Raf kinase inhibitory protein (RKIP), which appears to suppress tumor development. Additionally, this review discusses the efficacy of various treatments, such as molecular therapies that target specific pathways or inhibit neomorphic protein–protein interaction caused by NF2 deficiency. This overview not only expands on the fundamental understanding of NF2 pathophysiology but also explores the potential of novel therapeutic targets that affect the clinical approach to NF2 syndrome.

24 April 2023 in Cells
Verified
Journal Article
Open access
PDF file
SKSo-mi Kang
So-mi Kang
SSSeungwoon Seo
Seungwoon Seo
ESEunju Song
Eunju Song
OKOkhee Kweon
Okhee Kweon
AJAh-Hyeon Jo
Ah-Hyeon Jo
BPBum-Joon Park
Bum-Joon Park
Hutchinson–Gilford Progeria Syndrome (HGPS) is an ultra-rare human premature aging disorder that precipitates death because of cardiac disease. Almost all cases of HGPS are caused by aberrant splicing of the LMNA gene that results in the production of a mutant Lamin A protein termed progerin. In our previous study, treatment with Progerinin has been shown to reduce progerin expression and improve aging phenotypes in vitro and in vivo HGPS models. In this record, cardiac parameters (stroke volume (SV), ejection fraction (EF), fractional shortening (FS), etc.) were acquired in LmnaWT/WT and LmnaG609G/WT mice fed with either a vehicle diet or a Progerinin diet by echocardiography (from 38 weeks to 50 weeks at various ages), and then the cardiac function was analyzed. We also acquired the tissue samples and blood serum of LmnaWT/WT and LmnaG609G/WT mice for pathological analysis at the end of echocardiography. From these data, we suggest that the administration of Progerinin in the HGPS model mouse can restore cardiac function and correct arterial abnormalities. These observations provide encouraging evidence for the efficacy of Progerinin for cardiac dysfunction in HGPS.

1 February 2021 in Journal of Functional Foods
Verified
Journal Article
Open access
JAJinsook Ahn
Jinsook Ahn
TWTae-Gyun Woo
Tae-Gyun Woo
SKSo-mi Kang
So-mi Kang
IJInseong Jo
Inseong Jo
JWJae-Sung Woo
Jae-Sung Woo
NHNam-Chul Ha
Nam-Chul Ha

7 May 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
BKBae-Hoon Kim
Bae-Hoon Kim
YCYeon-Ho Chung
Yeon-Ho Chung
TWTae-Gyun Woo
Tae-Gyun Woo
SKSo-mi Kang
So-mi Kang
SPSoyoung Park
Soyoung Park
BPBum-Joon Park
Bum-Joon Park
Neurofibromatosis type 2 (NF2) is a genetic syndrome characterized by the growth of benign tumors in the nervous system, particularly bilateral vestibular schwannomas, meningiomas, and ependymomas. This review consolidates the current knowledge on NF2 syndrome, emphasizing the molecular pathology associated with the mutations in the gene of the same name, the NF2 gene, and the subsequent dysfunction of its product, the Merlin protein. Merlin, a tumor suppressor, integrates multiple signaling pathways that regulate cell contact, proliferation, and motility, thereby influencing tumor growth. The loss of Merlin disrupts these pathways, leading to tumorigenesis. We discuss the roles of another two proteins potentially associated with NF2-deficiency as well as Merlin: Yes-associated protein 1 (YAP), which may promote tumor growth, and Raf kinase inhibitory protein (RKIP), which appears to suppress tumor development. Additionally, this review discusses the efficacy of various treatments, such as molecular therapies that target specific pathways or inhibit neomorphic protein-protein interaction caused by NF2-deficiency. This overview not only expands on the fundamental understanding of NF2 pathophysiology but also explores the potential of novel therapeutic targets that affect the clinical approach to NF2 syndrome.